Matches in Wikidata for { <http://www.wikidata.org/entity/Q37695157> ?p ?o ?g. }
- Q37695157 description "article científic" @default.
- Q37695157 description "article scientifique" @default.
- Q37695157 description "articolo scientifico" @default.
- Q37695157 description "artigo científico" @default.
- Q37695157 description "artículu científicu espublizáu en 2016" @default.
- Q37695157 description "bilimsel makale" @default.
- Q37695157 description "scientific article published on 25 October 2016" @default.
- Q37695157 description "vedecký článok" @default.
- Q37695157 description "vetenskaplig artikel" @default.
- Q37695157 description "videnskabelig artikel" @default.
- Q37695157 description "vědecký článek" @default.
- Q37695157 description "wetenschappelijk artikel" @default.
- Q37695157 description "wissenschaftlicher Artikel" @default.
- Q37695157 description "наукова стаття, опублікована в жовтні 2016" @default.
- Q37695157 description "научни чланак" @default.
- Q37695157 description "مقالة علمية نشرت في 25 أكتوبر 2016" @default.
- Q37695157 name "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 name "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 name "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 type Item @default.
- Q37695157 label "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 label "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 label "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 prefLabel "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 prefLabel "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 prefLabel "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 P1433 Q37695157-C31A3EDA-0C66-4303-A9AC-9BC1926A3821 @default.
- Q37695157 P1476 Q37695157-6E9AD574-022F-4C8A-BC5C-A4CD6679F93C @default.
- Q37695157 P2093 Q37695157-26C39E40-10C9-4A10-AC43-D9CBC6D7798B @default.
- Q37695157 P2093 Q37695157-3007E95C-79A2-4F44-9C79-630F009F11EC @default.
- Q37695157 P2093 Q37695157-3D3A37D6-5A62-489C-9F06-91D285DA430D @default.
- Q37695157 P2093 Q37695157-7BC0A469-EF84-432E-9079-084854A36899 @default.
- Q37695157 P2093 Q37695157-E79C8D71-5A25-4A7B-A312-2A1755C8B067 @default.
- Q37695157 P2860 Q37695157-08B60FBE-92FD-4F55-AF6E-E3FC66F07367 @default.
- Q37695157 P2860 Q37695157-13F4A8A5-5DEA-43DE-A113-B293B8D4FA7F @default.
- Q37695157 P2860 Q37695157-24945166-4892-4369-A3C2-8E372F026C80 @default.
- Q37695157 P2860 Q37695157-28B25EEE-CADE-476A-B2CA-628C1AB01903 @default.
- Q37695157 P2860 Q37695157-2C736E6A-6123-4665-8FE1-E1C94D247D25 @default.
- Q37695157 P2860 Q37695157-31FBDBBC-9D46-44C5-8CD5-0C3BFFF1DC64 @default.
- Q37695157 P2860 Q37695157-463B6C95-3A7F-4242-AA61-54D4E015D000 @default.
- Q37695157 P2860 Q37695157-47B05A0E-2D7E-4F4F-A09A-9531C6C2F98A @default.
- Q37695157 P2860 Q37695157-494BBA9E-71C3-4A38-8BB0-871AD0BFCAC0 @default.
- Q37695157 P2860 Q37695157-49A1C045-0E61-4C67-BFE2-F0201CFFB200 @default.
- Q37695157 P2860 Q37695157-6BFE6170-5A54-4416-99F9-0733D4981ACC @default.
- Q37695157 P2860 Q37695157-806ACABD-0471-45AA-B4B5-4615116BC9EC @default.
- Q37695157 P2860 Q37695157-8BC742D3-558A-406D-91DB-110FA34816D5 @default.
- Q37695157 P2860 Q37695157-8EE9C733-124E-4EBE-960F-F02262DD7CC2 @default.
- Q37695157 P2860 Q37695157-90DB72EB-77C4-46CD-AAEF-ABAFB1168840 @default.
- Q37695157 P2860 Q37695157-9120FBE2-8C29-47CA-991C-F5F77D040A97 @default.
- Q37695157 P2860 Q37695157-939CECD2-37B0-4D24-865C-8254CFBE41F8 @default.
- Q37695157 P2860 Q37695157-A18530C7-8597-4A4B-AD4C-FB0946002632 @default.
- Q37695157 P2860 Q37695157-A413668F-74CE-4123-BC74-0D35AE03AC5D @default.
- Q37695157 P2860 Q37695157-A4CD7CF9-76C2-4B48-A7F2-3479CA4F694D @default.
- Q37695157 P2860 Q37695157-AB02277F-F103-4202-BACA-75519C175E22 @default.
- Q37695157 P2860 Q37695157-BFCB12DF-BC81-47CA-A1BF-9936FEC5877E @default.
- Q37695157 P2860 Q37695157-C212EA76-FE67-48B7-9B02-97A433BD74CA @default.
- Q37695157 P2860 Q37695157-C479F930-6221-4D31-852C-C1D10E54F4C7 @default.
- Q37695157 P2860 Q37695157-C69B4C9C-D5FF-452F-A0E3-B55FA936B52B @default.
- Q37695157 P2860 Q37695157-CA31343A-DD81-48D8-8DC9-02D7C6273ABD @default.
- Q37695157 P2860 Q37695157-CED38010-4A76-4065-8F0A-A5752D9BB4FE @default.
- Q37695157 P2860 Q37695157-D6B97384-C65D-4AED-BA56-62E911ADE11C @default.
- Q37695157 P2860 Q37695157-E7FEA802-882F-40B5-AFF4-0ACB3989F8FC @default.
- Q37695157 P2860 Q37695157-EB4D2509-D7F2-4275-BE60-7CCC28240405 @default.
- Q37695157 P2860 Q37695157-ECCD7771-75DA-4FA2-950F-DF066DD11D6A @default.
- Q37695157 P304 Q37695157-79E90B85-5EA0-4AAD-A351-061668B69470 @default.
- Q37695157 P31 Q37695157-1DF6CD83-5895-47DA-8A0C-DFB9119DDC19 @default.
- Q37695157 P356 Q37695157-D22B5D2D-8D7B-464F-A6BD-DA797EACBB62 @default.
- Q37695157 P433 Q37695157-46E0EFE3-683D-4C4B-95A5-D748BDBC87C2 @default.
- Q37695157 P478 Q37695157-FAD16E9D-DA16-449E-A466-11F80C5C0856 @default.
- Q37695157 P577 Q37695157-590411C1-1AF7-4C3A-A42E-112E4F176830 @default.
- Q37695157 P698 Q37695157-8D1B4F97-99B7-4EEF-9BD6-A53FA25F2316 @default.
- Q37695157 P921 Q37695157-08E7C2AD-45CD-4EEB-9224-914642820F7F @default.
- Q37695157 P921 Q37695157-A52680E6-984C-4D29-8964-245090854B85 @default.
- Q37695157 P921 Q37695157-BD130071-AFC5-4A03-8FB4-FC7554E52529 @default.
- Q37695157 P921 Q37695157-DDAB7A8B-A7C3-4A8E-B225-6B86AD7888DC @default.
- Q37695157 P932 Q37695157-23DA0545-4392-472C-BBEB-DB77EB137FE1 @default.
- Q37695157 P356 JAYAO.2016.0049 @default.
- Q37695157 P698 27779442 @default.
- Q37695157 P1433 Q26842491 @default.
- Q37695157 P1476 "Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults" @default.
- Q37695157 P2093 "David L Veenstra" @default.
- Q37695157 P2093 "Geertrui F Vanhove" @default.
- Q37695157 P2093 "Gregory F Guzauskas" @default.
- Q37695157 P2093 "Kathleen F Villa" @default.
- Q37695157 P2093 "Vicki L Fisher" @default.
- Q37695157 P2860 Q26784116 @default.
- Q37695157 P2860 Q31085634 @default.
- Q37695157 P2860 Q34123874 @default.
- Q37695157 P2860 Q34354175 @default.
- Q37695157 P2860 Q34454611 @default.
- Q37695157 P2860 Q34610024 @default.
- Q37695157 P2860 Q34679298 @default.
- Q37695157 P2860 Q35543165 @default.
- Q37695157 P2860 Q36200481 @default.
- Q37695157 P2860 Q36814162 @default.
- Q37695157 P2860 Q36843677 @default.
- Q37695157 P2860 Q36961822 @default.
- Q37695157 P2860 Q37883008 @default.
- Q37695157 P2860 Q37914185 @default.
- Q37695157 P2860 Q37990381 @default.